According to IMARC Group, the global angioplasty balloons market was valued at USD 2.6 Billion in 2025 and is projected to reach USD 3.3 Billion by 2034, expanding at a CAGR of 2.58% during 2026–2034. This steady growth reflects the increasing prevalence of cardiovascular diseases, a rising geriatric population, and continued advancements in balloon catheter technologies that are expanding the scope and safety of angioplasty procedures globally.

Angioplasty Balloons Industry Overview

Angioplasty balloons are catheter-mounted medical devices used to open narrowed or blocked blood vessels — primarily in coronary and peripheral arteries — by inflating inside the vessel to restore normal blood flow. The angioplasty balloons market analysis reveals a sector shaped by clinical innovation, rising cardiovascular disease burden, and the shift toward outpatient and ambulatory care settings. Key product categories include:

●        Normal Balloons: Standard devices used in routine angioplasty procedures for dilating constricted or blocked arteries

●        Cutting Balloons: Equipped with microsurgical blades for precision treatment of resistant lesions

●        Drug-Eluting Balloons (DEBs): Coated with anti-restenotic agents to reduce re-narrowing of the artery after treatment

●        Scoring Balloons: Feature scoring elements to create controlled incisions in calcified plaques for improved vessel expansion

These devices are used primarily in coronary angioplasty (treating heart artery blockages) and peripheral angioplasty (treating artery blockages in the legs, arms, and other non-cardiac vessels). The angioplasty balloons market size is bolstered by growing adoption across hospitals and ambulatory surgery centers (ASCs) seeking to provide cost-effective interventional care.

Global Market Overview & Angioplasty Balloons Market Statistics

Below are the key angioplasty balloons market statistics drawn from IMARC Group's comprehensive market analysis:

Request for a Sample Report for Detailed Angioplasty Balloons Market Analysis Evaluation: https://www.imarcgroup.com/angioplasty-balloons-market/requestsample

Key Market Drivers & Angioplasty Balloons Market Trends in 2026

Several powerful forces are shaping the angioplasty balloons market trends and driving steady global growth:

1. Increasing Prevalence of Cardiovascular Diseases (CVDs)

Cardiovascular diseases remain the leading cause of death globally, according to the WHO, which has amplified demand for angioplasty as a critical intervention. According to the Centers for Disease Control and Prevention (CDC), approximately 5% of adults aged 20 and above — roughly 1 in 20 individuals — suffer from coronary artery disease (CAD). This high and rising burden of heart disease is one of the most significant

Angioplasty Balloons Market Trends, directly fueling procedure volumes and device demand worldwide.

2. FDA Approvals and Next-Generation Balloon Technologies

Regulatory milestones are reshaping the competitive and clinical landscape. The FDA approval of Boston Scientific's AGENT Drug-Coated Balloon (DCB) in March 2024 for the treatment of coronary in-stent restenosis (ISR) marked a pivotal moment for the market. Additionally, in July 2024, the FDA approved the Ringer Perfusion Balloon Catheter by Teleflex — a novel device featuring a helical balloon design that maintains coronary blood flow during inflation. These approvals are accelerating adoption of advanced balloon solutions and expanding treatment options for complex cardiovascular conditions.

3. Rising Geriatric Population and Lifestyle-Related Risk Factors

The growing aging population — particularly in Asia-Pacific, where approximately 697 million people aged 60 and above reside (UNESCAP, 2023) — is a key structural driver of the angioplasty balloons market. Older populations are at significantly higher risk for cardiovascular diseases. Combined with sedentary lifestyles, dietary changes, smoking, diabetes, and hypertension, lifestyle-driven cardiovascular risk is amplifying the demand for angioplasty procedures globally.

4. Growing Demand for Minimally Invasive Procedures

Patients and healthcare systems are increasingly prioritizing minimally invasive treatments due to shorter recovery times, reduced procedural risks, and lower overall costs compared to open-heart surgery. Angioplasty balloon procedures align perfectly with this preference, contributing to their growing adoption as a first-line intervention for artery blockages, both coronary and peripheral.

5. Expanding Healthcare Infrastructure in Emerging Markets

Rapid development of healthcare infrastructure across Asia-Pacific, Latin America, and the Middle East & Africa is widening access to interventional cardiology services. In China alone, approximately 330 million cases of CVD have been reported (NCBI, 2023), creating enormous demand for effective treatments including angioplasty. As more facilities gain the capacity to perform these procedures, the addressable market for angioplasty balloons expands significantly.

6. Drug-Coated Balloon Innovations Reducing Stent Dependency

Drug-coated angioplasty balloons are gaining clinical acceptance due to their ability to deliver antiproliferative agents directly to the vessel wall, reducing restenosis without the complications associated with permanent metallic stents such as vessel fracture or late stent thrombosis. This stent-sparing approach is particularly valuable in complex lesion types and smaller vessel segments, making DCBs an increasingly preferred treatment modality.

Key Market Segmentation

By Product Type

Normal Balloons – Largest Segment (~54.8% market share in 2025)

Normal balloons hold the dominant position in the angioplasty balloons market due to their extensive clinical use, proven efficacy, and cost-effectiveness relative to specialized alternatives. They are the workhorse of routine angioplasty procedures across both developed and emerging healthcare settings, appreciated for their simplicity and reliable outcomes.

●        Cutting Balloons

●        Drug-Eluting Balloons

●        Scoring Balloons

By Application

Coronary Angioplasty – Largest Segment (~55.6% market share in 2025)

Coronary angioplasty holds the largest application segment due to the high global prevalence of coronary artery disease (CAD) — a leading cause of mortality worldwide. The rapid advancement of drug-coated balloon technologies specifically designed for coronary interventions has further strengthened this segment's dominance.

●        Peripheral Angioplasty

By Material

Nylon, Polyurethane, Silicone Urethane Co-Polymers, Others

Nylon leads due to its exceptional tensile strength and biocompatibility. Polyurethane is favored for its flexibility and ability to retain shape under high pressure. Silicone urethane co-polymers offer superior kink resistance and smooth surface properties.

By End User

Ambulatory Surgery Centers (ASCs) – Largest End-User Segment (~32% market share in 2025)

ASCs lead the end-user segment due to their ability to deliver minimally invasive angioplasty procedures at lower costs with greater operational efficiency. Their growing capability to perform angioplasty safely and accurately — supported by advancing balloon technologies — has made them the preferred setting for outpatient cardiovascular interventions.

●        Hospitals

●        Others

Regional Market Analysis

Connect for Detailed Segmentation Analysis – Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=2270&flag=C

Leading Players in the Angioplasty Balloons Industry

The global angioplasty balloons market features a highly competitive landscape, with major medical device corporations competing alongside specialized cardiovascular device makers. Key companies covered in the IMARC Group report include:

●        Abbott Laboratories

●        B. Braun Melsungen AG

●        BD (Becton, Dickinson, and Company)

●        Biotronik SE & Co. KG

●        Boston Scientific Corporation

●        Cardinal Health Inc.

●        Cook Medical LLC

●        Endocor GmbH & Co. KG

●        Johnson & Johnson

●        Medtronic Inc.

●        Terumo Corporation

The report includes competitive analysis covering market structure, player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant.

Latest Industry Developments

November 2024 – DCB-BIF Trial at TCT 2024

The DCB-BIF trial was presented at TCT 2024, examining the effectiveness of drug-coated balloons in treating side branches of coronary bifurcation lesions following provisional stenting, in comparison to non-compliant balloons — an important step in expanding DCB clinical evidence.

July 2024 – FDA Approval of Ringer Perfusion Balloon Catheter (Teleflex)

The FDA approved the Ringer Perfusion Balloon Catheter (PBC) — the first catheter for percutaneous transluminal coronary angioplasty featuring a helical balloon design. The innovation maintains coronary blood flow during balloon inflation, enhancing myocardial perfusion and enabling delivery of additional devices during the procedure.

March 2024 – FDA Approves Boston Scientific AGENT Drug-Coated Balloon

Boston Scientific received FDA approval for its AGENT drug-coated balloon for treating coronary in-stent restenosis (ISR) — representing the most critical regulatory milestone in DCB adoption for coronary interventions in recent years.

January 2025 – Concept Medical MAGICAL Study Enrollment Begins

Florida-based Concept Medical announced enrollment of the first patient in its MAGICAL study, comparing a sirolimus-coated balloon to standard angioplasty for patients with peripheral artery disease (PAD) below the knee, following successful FDA Investigational Device Exemption (IDE) approval for the MagicTouch PTA.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Energy, Chemicals, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104